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Abstract
Background: Urotensin II (U-II) is a cyclic peptide originally isolated from the neurosecretory system of the teleost fish and
subsequently found in other species, including man. U-II was identified as the natural ligand of a G-protein coupled
receptor, namely UT receptor. U-II and UT receptor are expressed in a variety of peripheral organs and especially in
cardiovascular tissue. Recent evidence indicates the involvement of U-II/UT pathway in penile function in human, but the
molecular mechanism is still unclear. On these bases the aim of this study is to investigate the mechanism(s) of U-II-induced
relaxation in human corpus cavernosum and its relationship with L-arginine/Nitric oxide (NO) pathway.
Methodology/Principal Findings: Human corpus cavernosum tissue was obtained following in male-to-female transsexuals
undergoing surgical procedure for sex reassignment. Quantitative RT-PCR clearly demonstrated the U-II expression in
human corpus cavernosum. U-II (0.1 nM–10 mM) challenge in human corpus cavernosum induced a significant increase in
NO production as revealed by fluorometric analysis. NO generation was coupled to a marked increase in the ratio eNOS
phosphorilated/eNOS as determined by western blot analysis. A functional study in human corpus cavernosum strips was
performed to asses eNOS involvement in U-II-induced relaxation by using a pharmacological modulation. Pre-treatment
with both wortmannin or geldanamycinin (inhibitors of eNOS phosphorylation and heath shock protein 90 recruitment,
respectively) significantly reduced U-II-induced relaxation (0.1 nM–10 mM) in human corpus cavernosum strips. Finally, a co-
immunoprecipitation study demonstrated that UT receptor and eNOS co-immunoprecipitate following U-II challenge of
human corpus cavernosum tissue.
Conclusion/Significance: U-II is endogenously synthesized and locally released in human corpus cavernosum. U-II elicited
penile erection through eNOS activation. Thus, U-II/UT pathway may represent a novel therapeutical target in erectile
dysfunction.
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Introduction
Urotensin II (U-II) is a cyclic peptide hormone derived from
pre-pro-U-II by urotensin-converting enzyme. It was first isolated
from teleost fish and homologues subsequently were identified
across the evolutionary spectrum, including mammals and man.
U-II causes both vasoconstriction and vasodilation depending by
the vascular district and the species considered [1–6]. Its
vasoactive effect is mediated by binding to a GPR14 (UT
receptor), a G protein-coupled receptor [7]. U-II is secreted from
heart and several other tissues into the circulation [8]. However,
the source of U-II production in the human body remains to be
elucidated. Both U-II and UT receptor are expressed widely
within the cardiovascular system, and their expression is up-
regulated in human cardiovascular disease, including congestive
heart failure, hypertension, type II diabetes and diabetic
nephropathy [9–11]. Collectively, these data indicate U-II as
potential modulator of cardiovascular homeostasis in human.
Recently, we have demonstrated the involvement of U-II/UT
pathway in erectile function [12]. Indeed, an intra-cavernous
injection of U-II in rats causes an increase in intra-cavernous
pressure without affecting systemic blood pressure. It has also been
demonstrated that UT receptor is present in human corpus
cavernosum (HCC). It is located on the endothelium and it
mediates an endothelium-dependent relaxation involving the L-
arginine/nitric oxide (NO) pathway [12]. It is well established that
the L-arginine/NO pathway plays a major role in erectile function
in man [13,14]. NO is produced by a group of enzymes called
nitric oxide synthase (NOS) that by converting L-arginine into L-
citrulline produce NO [15,16]. The endothelial NOS (eNOS) is
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regulated and produces physiologically relevant levels of NO.
The regulation of eNOS involves multiple molecular mecha-
nisms that act in concert to both positively or negatively affect the
function of this enzyme. eNOS is classified as a constitutive and
strictly calcium/calmodulin-dependent enzyme [17]. The calcium
levels as well as the heath shock protein 90 (Hsp90) recruitment
increase the catalytic activity of eNOS [18,19]. The eNOS-
associated Hsp90 may also serve as a scaffolding protein,
facilitating the organization of additional associated regulatory
proteins. In addition, fluid shear stress or other stimuli by
phosphorylation can shift eNOS to an higher state of activation
[20]. For example, bradykinin enhances eNOS phosphorylation;
this effect is maximal after 5 minutes and it is maintained for at
least 20 minutes in cultured endothelial cells [21]. In recent years,
it has been reported that eNOS phosphorylation at serine
1177 by
phosphatydilinositol 3 kinase (PI3K)/protein kinase B (Akt) is
critical for the maintenance of full penile erection [22,23]. Thus
eNOS activity is finely regulated and can shift to an higher degree
of activation following molecular modulation [17–23].
The present study investigates the relationship between U-II/
UT and L-arginine/NO pathway in human corpus cavernosum.
Our data demonstrate that U-II pro-erectile response relies on
eNOS-derived NO, contributing to the maintenance of full penile
erection.
Results
U-II is present as mRNA in HCC
The RT-PCR analysis (Figure 1) clearly demonstrated the U-II
presence in HCC samples. Since it has been reported that U-II is
over-expressed in human tumoural cell lines SW-13 [24], a
positive control by using SW-13 cells was performed, too. No
amplifications were observed when PCR was performed in same
conditions but without cDNA.
Taken together, these data demonstrate that U-II can be locally
synthesized and endogenously released in HCC.
U-II vasorelaxant effect involves eNOS activation
As previously described U-II causes an endothelium- and NO-
dependent relaxation in pre-contracted HCC strips [12]. A
pharmacological eNOS modulation was operated by using
inhibitors that either interfere with Hsp90 recruitment (geldani-
mycin) or inhibit phosphorylation (wortmannin). Both wortman-
nin (0.1 mM) or geldanamycin (1 mM) significantly reduced U-II
induced relaxation of human tissues (Figure 2 A, ***p,0.001 and
**p,0.01).
U-II promotes NO production in HCC
In order to confirm the NO involvement in U-II/UT signaling
we evaluated the NO production in HCC homogenate tissues
stimulated with U-II (1 nM–10 mM). Data, expressed as total
nitrite, clearly showed that U-II caused a significant increase in
NOx production compared with vehicle (Figure 2 B, *p,0.05,
**p,0.01, ***p,0.001).
U-II induces eNOS phosphorylation in HCC
To further asses the U-II involvement in eNOS activation we
performed a western blot study. The protein expression of eNOS
as well as phosphorylated eNOS
Ser 1177 (p-eNOS) in tissues
incubated with U-II (10 mM), at scheduled time, was evaluated. U-
II induced eNOS phosphorylation in a time-dependent manner,
reaching its maximum at 30 minutes (Figure 3 A, *p,0.05). Thus
30 minutes of incubation has been chosen as the time point to
perform the experiments by using inhibitors. Wortmaninn
(0.1 mM), an irreversible inhibitor of PI3K, but not geldamycin,
reverted significantly eNOS phosphorylation induced by U-II
challenge (***p,0.001, Figure 3 B).
U-II induces the recruitment of eNOS to UT receptor in
HCC
The co-immunoprecipation assay allows to identify protein-
protein/enzyme interaction. Thus, to confirm the relation
between U-II/UT pathway and eNOS, we performed the eNOS
precipitation and monitored the co-precipitation of UT receptor in
HCC tissues incubated for 30 minutes with U-II (10 mM) or
vehicle. U-II induced the formation of the immunocomplex
between UT and eNOS (Figure 4).
Discussion
Human penile erection is a resultant of several complex
mechanisms. A key issue is the balance between contracting and
relaxant factors which are instrumental in order to achieve penile
erection. It is now well accepted that NO plays a major role in
induction and maintenance of erection [25–28]. Recently we have
reported that U-II-induced relaxation in HCC is endothelium-
and NO-dependent [12]. On this basis we have proposed that U-
II, physiologically circulating in our body [8], contributes to penile
homeostasis. Our present finding further extends the importance
of this signaling pathway and confirms that endothelium is
necessary.
We have demonstrated that mRNA for U-II is present in the
human tissue. This finding indicates that U-II can be locally
endogenously synthesized within the HCC and that U-II/UT
pathway is involved within erection physiology. The exclusive
presence of UT receptor on the endothelial cells in human penile
tissue [12] further corroborates this concept. Based on this and our
previous finding, we have hypothesized an interaction between
UT receptor and eNOS at molecular level within the endothelium.
Following this hypothesis we performed a co-immunoprecipitation
study. The formation of the immunocomplex demonstrated that a
link exists between eNOS and U-II/UT pathway within the
human penile tissue. This molecular evidence was functionally
confirmed. Indeed, the incubation of HCC homogenates with U-
II caused a concentration-dependent increase in NOx production.
Figure 1. Quantitative RT-PCR for U-II in HCC. U-II is expressed as
mRNA in HCC samples. Human tumoural cells SW-13 were used as
positive control. Data were normalized on the basis of GAPDH and
expressed as mean 6 standard error of the mean (SEM) of three
different human specimens.
doi:10.1371/journal.pone.0031019.g001
eNOS Involvement in U-II Induced Penile Erection
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increase in NOx generation. Thus, U-II released within the corpus
cavernosum binds its receptor on endothelial cells leading to
eNOS activation and in turn to NO production. Basically, U-II-
induced relaxation contributes to eNOS-derived NO generation in
HCC. But how activation of this pathway leads to an increase
production of eNOS-derived NO? To date it is well consolidate
the concept that neuronal NOS (nNOS) and eNOS mediate the
initiation and maintenance of penile erection, respectively [22].
Neuronal signal initiates penile erection by activating nNOS that
elicits a rapid and transient NO release causing an increase in
blood flow [29]. The resulting shear stress force on the
endothelium activates the PI3K/Akt/eNOS phosphorylation
cascade, causing more sustained NO release and relaxation
[22,30]. Indeed, Akt-phoshorylated eNOS results 15 to 20 fold
more active that un-phospohorylated eNOS [31]. In other words,
the phosphorylation of eNOS shifts the enzyme at higher state of
activation, boosting NO production [32].
In the human body, the penis is one of the organ physiologically
subjected to shear stress and the resultant eNOS phosphoryla-
tion
Ser1177 plays a key role in the maintenance of full penile
erection [22]. Therefore, we performed a pharmacological
modulation of the eNOS phosphorylation in order to investigate
if U-II activity relies on this mechanism. U-II caused a significant
increase in eNOS phosphorylation
Ser1177 in a time-dependent
manner. The irreversible inhibition of PI3K/Akt operated by
wortmannin, reverted the phosphorylation induced by U-II. Also
in this case the molecular finding has been confirmed through a
Figure 2. Panel A: U-II induced concentration-response curve (0.1 nM–10 mM) in HCC strips was significantly inhibited by pre-
treatment with wortmannin (0.1 mM), PI3K inhibitor, or geldanamycin (1 mM) Hsp90 inhibitor (***p,0.001 and ** p,0.01 versus
vehicle). Data were expressed as the mean 6 standard error of the mean (SEM) of six different specimens. Data were analyzed by ANOVA followed
by Bonferroni post test. Panel B: NOx (total nitrite) production in HCC tissue incubated with U-II (1 nM-10 mM) or vehicle for 30 min. U-II caused a
significant increase in NO production compared with vehicle (*p,0.05, **p,0.01, ***p,0.001). Data were expressed as mean 6 standard error of the
mean (SEM) from four different specimens and analyzed by ANOVA followed by Bonferroni post test.
doi:10.1371/journal.pone.0031019.g002
Figure 3. Western blot analysis for eNOS and p-eNOS
Ser-1177 in HCC tissue. Panel A: U-II (10 mM) caused an increase in eNOS
phosphorylation expressed as p-eNOS/eNOS ratio in a time-dependent manner (*p,0.05 vs vehicle). Panel B: U-II-induced eNOS phosphorylation
(**p,0.01 vs vehicle), was significantly reverted by wortmannin (0.1 mM), PI3K inhibitor, (up,0.05 vs U-II) but not by geldanamicin (1 mM), Hsp90
inhibitor. Data were expressed as the mean 6 standard error of the mean (SEM) of four different specimens and were analyzed by ANOVA followed
by Bonferroni post test.
doi:10.1371/journal.pone.0031019.g003
eNOS Involvement in U-II Induced Penile Erection
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virtually abolished by wortmannin.
Another recognized key player in the mechanism of eNOS
activation is Hsp90. In fact, shear stress as well as some other
endogenous substances enhances the interaction between Hsp90
and eNOS [18,19]. The increased association of eNOS to Hsp90
shifts the enzyme to an higher active state, too. Basically, Hsp90
acts as an allosteric modulator of eNOS by inducing conforma-
tional changes in the enzyme that result in an increased activity
[33]. Geldanamycin, an Hsp 90 inhibitor, blocked U-II induced
relaxation of HCC strips at the same extent of wortmannin.
Experimental evidence suggests that Hsp90-eNOS hetero-com-
plex occurs simultaneously with other signaling events such as the
mobilization of intracellular calcium and/or protein phosphory-
lation [34]. Therefore, it appears feasible the U-II/UT pathway
contributes to the maintenance rather than triggering erection.
Indeed, the pro-erectile effect of U-II is strictly dependent upon
eNOS derived-NO generation. The obligatory role for eNOS-
derived NO in U-II effect is supported by the finding that i)
blockade of eNOS phosphorylation and Hsp90 coupling abrogates
U-II effect ii) incubation of HCC tissue with U-II causes a notable
increase in NO generation.
In conclusion , U-II/UT pathway contributes to the physiology
of erection through eNOS-derived NO. UII/UT pathway once
activated, most likely by the shear stress due to the erection, causes
eNOS phosphorylation and Hsp90 recruitment shifting eNOS
activity to a more activate state. This in turn leads to a sustained
NO release which contribute to the maintenance of the ongoing
erection.
Thus, U-II/UT pathway could represent an important novel
target in order to find new pharmacological approaches in erectile
dysfunction. Indeed, it is known that a certain percent of patients
(about 35%) do not respond to PDE5 inhibitors [35]. As PDE5
inhibitors and U-II share the same target NO, it is plausible that in
the next future U-II agonists might be used in combination with
PDE5 inhibitors in order to enhance cGMP signaling. Indeed, it
could be that in some cases there is only a limited amount of
endothelium functionally working and the PDE5 inhibition by
itself will not be sufficient to sustain the erection triggered. In this




The human U-II was synthesized and purified at the
Department of Pharmaceutical and Toxicological Chemistry of
the University of Naples, Federico II. The peptide was obtained by
solid-phase peptide synthesis as previously reported [36]. Purifi-
cation was achieved using a semi-preparative reversed phase high-
performance liquid chromatography (HPLC) C18 bonded silica
column (Vydac 218TP1010; The Separations Group Inc.,
Hesperia, CA, USA). The purified peptide was 99% pure as
determined by analytical reversed-phase HPLC. The correct
molecular weight were confirmed by mass spectrometry and
amino acid analysis.
Human Tissue
In male-to-female transsexuals undergoing surgical procedure
for sex reassignment, the penis and testicles were amputated and a
neo-vagina was created to simulate female external genitalia. All
the surgical procedures were performed at the Department of
Urology, University of Naples, Federico II, Naples, Italy [37]. The
corpora cavernosa were carefully excised from the penis
immediately after amputation and placed in ice-cold oxygenated
Krebs’ solution [37]. All patients were informed of all procedures
and gave their written consent. Local Ethical Committee (Faculty
of Medicine and Surgery; University of Naples Federico II, via
Pansini, 5; 80131, Naples, Italy) approved the use of human
corpus cavernosum tissue for in vitro studies.
Real-Time Quantitative Reverse Transcriptase Polymerase
Chain Reaction (RT-PCR)
The presence of U-II was determined by quantitative PCR.
Briefly, total RNA from omogenated HCC tissue was extracted by
using TRIzol reagent (Invitrogen, Milan, Italy), to eliminate
genomic DNA contamination 1 mg of above RNA was treated
with RQ1 RNase-free DNase I (Promega Corporation, Madison,
USA), according to the manufacturer’s recommendations. Reverse
transcription was performed using M-MLV Reverse Transcriptase
(Invitrogen, Milan, Italy) according to the manufacturer’s
recommendations, and 20 ng of cDNA samples were used for
quantitative PCR. Samples were run in triplicate in 25-mL
reactions using an 7500 Real Time PCR System (Applied
Biosystems, Foster City, CA). Amplification was done using Sybr
Green PCR Master Mix (Applied Biosystems, Monza, Italy). U-II-
specific forward primers 59-GCACTGTTTGCTTTGGACTCC-
39and reverse primer : 59-TGGTCGTCCATGCACAGATT-39,
and human GAPDH forward primer 59-AACGGATTTGGTCG-
TATTGGGC- 39 and reverse primer 59-TCGCTCCTGGAA-
GATGGTGATG-39 were specifically designed using Primer
Express Software 2.0 and validated for their specificity. Samples
were incubated at 50uC for 2 min and at 95uC for 10 min
followed by 40 cycles at 95uC for 15 s and 60uC for 1 min.
Differences in cDNA input were corrected by normalizing signals
obtained with primers specific for glyceraldehydes-3-phosphate
dehydrogenase (GAPDH). To exclude nonspecific amplification
and/or the formation of primer dimers, control reactions were
performed in the absence of target cDNA. In order to validate the
results we used human tumoural cell lines SW-13 as positive
control [24]. Gene expression levels were calculated using the
2
2DCT method and are presented as ratio between mean fold
change of target gene and GAPDH 6 standard error. Data were
expressed as mean 6 standard error of the mean (SEM) from
three different specimens.
NOx determination
HCC tissues were incubated with U-II at different concentra-
tion (1 nM–10 mM) or vehicle for 30 minutes at 37uC. The
reaction was stopped in liquid nitrogen. Homogenate tissues were
incubated in a microplate with cadmium (50 mg/well) for 1 h to
convert the inorganic anions nitrate (NO3) to nitrite (NO2). After
centrifugation at 14,000 rpm for 15 min, total nitrite (NOx)
Figure 4. Co-immunoprecipitation analysis of UT receptor and
eNOS. Tissues were stimulated with either vehicle (A) or U-II (C), lysates
were incubated with mouse anti-eNOS. Lanes B and D correspond to
the negative control of A and C, respectively. The western blot was
probed with rabbit anti-GPR14 (UT receptor). U-II but not vehicle
caused the co-immunoprecipation between eNOS and UT receptor.
doi:10.1371/journal.pone.0031019.g004
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(PerkinElmer Instruments, LS55; UK) using a standard curve of
sodium nitrite [38]. NOx content was calculated by using the
internal standard curve. Data were expressed as mean 6 standard
error of the mean (SEM) from four different specimens and
analyzed by using analysis of variance (ANOVA) followed by
Bonferroni post hoc test. The level of statistical significance was
taken as p,0.05.
Functional reactivity of HCC Strips
Longitudinal strips (2 cm) of HCC were dissected and isolated
from the trabecular structure of the penis [25]. Krebs’ solution had
the following composition (mM): 115.3 NaCl; 4.9 KCl; 1.46
CaCl2; 1.2 MgSO4; 1.2 KH2PO4; 25.0 NaHCO3; 11.1 glucose
(Carlo Erba, Milan, Italy). HCC strips were mounted in organ
bath containing oxygenated (95% O2 and 5% CO2) Krebs’
solution at 37uC. HCC strips were connected to isometric force-
displacement transducers (model 7002, Ugo Basile, Comerio,
Italy) and changes in tension were recorded continuously by using
a software (Datacapsule, Basile, Comerio, Italy). Tissues were
preloaded with 2 g of tension and allowed to equilibrate for
90 minutes in Krebs’ solution. After equilibration, tissues were
standardized by performing repeated phenylephrine (PE; 3 mM;
Sigma, Milan, Italy) contractions until three equal responses were
obtained. Endothelial integrity was assessed by using acetylcholine
(Ach; 0.01–10 mM; Sigma, Milan, Italy) and tissues that showed a
relaxation effect less that 80% were discarded. A concentration
response curve to U-II (0.1 nM–10 mM) was obtained in the
presence of endothelium, using HCC strips pre-contracted with
PE (3 mM). In order, to investigate the involvement of L-arginine/
NO pathway in U-II-induced relaxation we operated a pharma-
cological modulation. HCC strips were incubated for 30 minutes
with either wortmannin (0.1 mM, Tocris, UK) an irreversible
inhibitor of PI3K or geldanamycin (1 mM, Sigma, Milan, Italy) an
Hsp90 inhibitor before U-II challenge. The doses of wortmannin
(0.1 mM) and geldamycin (1 mM) were selected by a preliminary
dose-finding study (data not shown).
Data were calculated as % of relaxation to PE tone and
expressed as the mean 6 standard error of the mean (SEM) of six
different specimens. The results were analyzed by using analysis of
variance (ANOVA) followed by Bonferroni post hoc test. The level
of statistical significance was taken as p,0.05.
Western Blot Analysis
In order to evaluate the effect of U-II on the eNOS
phopsphorylation -Ser 1177 (p-eNOS
Ser 1177), HCC tissues were
incubated with the peptide (10 mM) at scheduled time (5, 15, 30
and 60 minutes). In another set of experiments, tissues were pre-
treated with wortmannin (0.1 mM, Tocris, UK) or geldamycin
(1 mM, Sigma, Milan, Italy) and thereafter incubated with U-II
(10 mM) or vehicle for 30 minutes. Next, HCC tissues were
homogenized in modified RIPA buffer (Tris-HCl 50 mM, pH 7.4,
Triton 1%, sodium deoxycholate 0.25%, NaCl 150 mM,
ethylenediaminetetraacetic acid 1 mM, phenylmethylsulphonyl
fluoride 1 mM, aprotinin 10 mg/mL, leupeptin 20 mM, NaF
1 mM, sodium orthovanadate 1 mM) by liquid nitrogen. Protein
concentration was estimated by the Bio-Rad protein assay using
bovine serum albumin (BSA) as standard. Equal amounts of
protein (50 mg) of the tissue lysates were separated on 8% sodium
dodecyl sulfate polyacrylamide gels and transferred to a poly-
vinylidene fluoride membrane. Membranes were blocked by
incubation in phosphate-buffered saline (PBS) containing 0.1%
v/v Tween 20, non fat dry milk (5%) and NaF (50 mM) for
1 hours, followed by overnight incubation at 4uC with rabbit anti-
p-eNOS
Ser-1177 polyclonal antibody (1:1000, Cell Signaling, DBA,
Italy) and with mouse eNOS monoclonal antibody (1:1000; BD
Transduction Laboratories). The filters were washed extensively in
PBS containing 0.1% v/v Tween 20, before incubation for
2 hours with horseradish peroxidase-conjugate anti rabbit second-
ary antibody (1:5000). Membranes were then washed and
developed using enhanced chemiluminescence substrate (Amer-
sham Pharmacia Biotech, San Diego, CA, USA). The data were
evaluated by densitometric analysis and expressed as p-eNOS/
eNOS ratio.
Data were expressed as mean 6 standard error of the mean
(SEM) of four different specimens. The results were analyzed by
using analysis of variance (ANOVA) followed by Bonferroni post
hoc test. The level of statistical significance was taken as p,0.05.
UT receptor and eNOS co-immunoprecipitation
HCC samples were homogenized (500 mg) and incubated with
20 ml of Protein A–coupled sepharose beads and 1 mg/ml of IgG
mouse at 4uC for 3 h. The samples were centrifuged (600 rpm for
15 sec) and the supernatants were incubated overnight at 4uC with
20 ml of mouse eNOS monoclonal antibody (Cell Signaling, DBA,
Milan, Italy) or normal mouse serum (to evaluate non-specific
binding) on a rotating wheel.Next, the samples were incubated
with 40 ml of Protein A–coupled sepharose beads at 4uC for 2 h
and centrifuged (600 rpm for 15 sec). The pellets were extensively
washed and then suspended in 36Laemmly buffer. After heating
at 95uC for 5 minutes, samples were subjected to Western blot
analysis developed for UT (1:1000; GPR14 (H-90), Santa Cruz
Biotechnology Inc., Heidelberg, Germany).
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